Περίληψη:
Aim. - Experimental evidence suggests that osteocalcin is a key
messenger that affects both adipocytes and insulin-producing beta cells.
Epidemiological cross-sectional studies have shown a negative
association between plasma levels of osteocalcin and glucose. For this
reason, the hypothesis that lower baseline osteocalcin plasma levels are
associated with diabetes was prospectively tested.
Methods. - The study population consisted of individuals at high risk
for type 2 diabetes who were screened for participation in the Greek arm
of a European type 2 diabetes prevention study (the DE-PLAN study). All
participants were free of diabetes at baseline and underwent a second
evaluation 3 years later. Diabetes status was defined according to an
oral glucose tolerance test.
Results. - A total of 307 subjects were included in the present
analysis. The population, including 154 men (50.3%), was middle-aged
(54.4 +/- 10.2 years) and overweight (BMI: 29.5 +/- 4.9 kg/m(2)). At
baseline, mean total plasma osteocalcin was lower in those with impaired
fasting glucose and/or impaired glucose tolerance compared with those
with normal glucose tolerance (6.0 +/- 3.1 ng/mL vs. 7.3 +/- 4.0 ng/mL,
respectively; P = 0.01). After 3 years, 36 subjects had developed
diabetes. In the prospective evaluation, there was no association
between baseline osteocalcin levels and diabetes (OR: 1.04 per 1 ng/mL,
95% CI: 0.93-1.15; P = 0.49) on multivariable logistic regression
analysis, nor was there any correlation with changes in plasma glucose
after 3 years (r = 0.09, P = 0.38).
Conclusion. - Our prospective results show that lower levels of
circulating osteocalcin do not predict future diabetes development and,
in contrast to most cross-sectional published data so far, suggest that
this molecule may not be playing a major role in glucose homoeostasis in
humans. (C) 2014 Elsevier Masson SAS. All rights reserved.
Συγγραφείς:
Liatis, S.
Sfikakis, P. P.
Tsiakou, A.
Stathi, C. and
Terpos, E.
Katsilambros, N.
Makrilakis, K.
